Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing 100853, China.
World J Gastroenterol. 2019 Jan 14;25(2):245-257. doi: 10.3748/wjg.v25.i2.245.
To evaluate the effectiveness and safety of submucosal tunneling endoscopic resection (STER) and compare its outcomes in esophageal and cardial submucosal tumors (SMTs) of the muscularis propria (MP) layer.
From May 2012 to November 2017, 173 consecutive patients with upper gastrointestinal (GI) SMTs of the MP layer underwent STER. Overall, 165 patients were included, and 8 were excluded. The baseline characteristics of the patients and SMTs were recorded. The resection rate, complete resection rate, residual rate, and recurrence rate were calculated to evaluate the effectiveness of STER, and the complication rate was recorded to evaluate its safety. Effectiveness and safety outcomes were compared between esophageal and cardial SMTs.
One hundred and twelve men and 53 women with a mean age of 46.9 ± 10.8 years were included. The mean tumor size was 22.6 ± 13.6 mm. Eleven SMTs were located in the upper esophagus (6.7%), 49 in the middle esophagus (29.7%), 46 in the lower esophagus (27.9%), and 59 in the cardia (35.7%). Irregular lesions accounted for 48.5% of all lesions. STER achieved an resection rate of 78.7% (128/165) for GI SMTs with an overall complication rate of 21.2% (35/165). All complications resolved without intervention or were treated conservatively without the need for surgery. The resection rates of esophageal and cardial SMTs were 81.1% (86/106) and 72.1% (42/59), respectively ( = 0.142), and the complication rates were 19.8% (21/106) and 23.7% (14/59), respectively, ( = 0.555). The most common complications for esophageal SMTs were gas-related complications and fever, while mucosal injury was the most common for cardial SMTs.
STER is an effective and safe therapy for GI SMTs of the MP layer. Its effectiveness and safety are comparable between SMTs of the esophagus and cardia.
评估黏膜下隧道内镜切除术(STER)的有效性和安全性,并比较其在食管和贲门固有肌层黏膜下肿瘤(SMT)中的结果。
2012 年 5 月至 2017 年 11 月,连续 173 例上消化道(GI)固有肌层 SMT 患者接受了 STER。共纳入 165 例患者,排除 8 例。记录患者和 SMT 的基线特征。计算切除率、完全切除率、残留率和复发率,以评估 STER 的有效性,并记录并发症发生率,以评估其安全性。比较食管和贲门 SMT 的有效性和安全性结果。
112 例男性和 53 例女性,平均年龄为 46.9±10.8 岁。平均肿瘤大小为 22.6±13.6mm。11 例 SMT 位于食管上段(6.7%),49 例位于食管中段(29.7%),46 例位于食管下段(27.9%),59 例位于贲门(35.7%)。不规则病变占所有病变的 48.5%。STER 对 GI SMT 的 切除率为 78.7%(128/165),总体并发症发生率为 21.2%(35/165)。所有并发症均无需干预即可自行缓解,或经保守治疗无需手术即可治愈。食管和贲门 SMT 的 切除率分别为 81.1%(86/106)和 72.1%(42/59)( = 0.142),并发症发生率分别为 19.8%(21/106)和 23.7%(14/59)( = 0.555)。食管 SMT 最常见的并发症为与气体相关的并发症和发热,而贲门 SMT 最常见的并发症为黏膜损伤。
STER 是治疗 GI 固有肌层 SMT 的一种有效且安全的方法。其在食管和贲门 SMT 中的有效性和安全性相当。